AF-399 42016530

A potent CCR4 antagonist that blocked CCL22- and CCL17-mediated migration of human peripheral blood CD4+CD25+ Treg and Th2 cells ex-vivo and murine Tregs in-vivo; enhances DC-mediated human CD4(+) T cell proliferation in an in vitro immune response model and amplifies cellular and humoral immune responses in vivo in experimental models, induces antigen-specific CD8+ T cells and tumor immunity against self antigens in combination with vaccines.

References 1. Klein A, et al. Oncotarget. 2017 May 9;8(19):31079-31091. 2. Bayry J, et al. Proc Natl Acad Sci U S A. 2008 Jul 22;105(29):10221-6. 3. Pere H, et al. Blood. 2011 Nov 3;118(18):4853-62. View Related Products by Target Chemokine Receptor (CCR and CXCR)